Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
Allergy Therapeutics (AGYTF) had Operating Cash Flow per Share of $-0.01 for the most recently reported fiscal year, ending 2025-06-30.
| Income Statement Financials | |
$71.23M |
|
$-51.93M |
|
$33.31M |
|
$37.92M |
|
$113.18M |
|
$-41.95M |
|
$-8.78M |
|
$-50.73M |
|
$-50.73M |
|
$-51.93M |
|
$-51.93M |
|
$-51.93M |
|
$-51.93M |
|
$-41.95M |
|
$-36.55M |
|
4.77B |
|
4.77B |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$44.88M |
|
$23.33M |
|
$42.53M |
|
$87.41M |
|
$35.19M |
|
$75.33M |
|
$88.70M |
|
$123.89M |
|
$-36.50M |
|
$-41.99M |
|
$-36.48M |
|
4.77B |
|
| Cash Flow Statement Financials | |
$-36.38M |
|
$-3.73M |
|
$40.33M |
|
$16.71M |
|
$16.55M |
|
$-0.16M |
|
$1.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.28 |
|
-- |
|
-- |
|
1.94 |
|
-2.13 |
|
53.23% |
|
-58.89% |
|
-58.89% |
|
-51.31% |
|
-71.22% |
|
-72.91% |
|
$-40.60M |
|
-- |
|
-- |
|
-- |
|
0.81 |
|
1.85 |
|
6.90 |
|
52.86 |
|
142.30% |
|
123.68% |
|
-59.42% |
|
-133.70% |
|
$-0.01 |
|
$-0.01 |
|
|
Operating Cash Flow per Share |
$-0.01 |